Last reviewed · How we verify
carboplatin and nab paclitaxel
carboplatin and nab paclitaxel is a Chemotherapy combination (platinum agent + taxane) Small molecule drug developed by Shanghai Henlius Biotech. It is currently in Phase 3 development for Non-small cell lung cancer (phase 3 development), Ovarian cancer (potential indication).
This combination uses carboplatin to cross-link DNA and nab-paclitaxel to stabilize microtubules, together inducing cancer cell death through complementary cytotoxic mechanisms.
This combination uses carboplatin to cross-link DNA and nab-paclitaxel to stabilize microtubules, together inducing cancer cell death through complementary cytotoxic mechanisms. Used for Non-small cell lung cancer (phase 3 development), Ovarian cancer (potential indication).
At a glance
| Generic name | carboplatin and nab paclitaxel |
|---|---|
| Sponsor | Shanghai Henlius Biotech |
| Drug class | Chemotherapy combination (platinum agent + taxane) |
| Target | DNA (carboplatin); β-tubulin (nab-paclitaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin is a platinum-based alkylating agent that forms DNA adducts, preventing replication and transcription. Nab-paclitaxel (albumin-bound paclitaxel) binds to β-tubulin and stabilizes microtubules, disrupting mitotic spindle formation. The combination exploits synergistic cell-cycle effects: carboplatin causes DNA damage while paclitaxel arrests cells in G2/M phase, enhancing overall cytotoxicity.
Approved indications
- Non-small cell lung cancer (phase 3 development)
- Ovarian cancer (potential indication)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Nausea and vomiting
- Fatigue
- Alopecia
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (PHASE3)
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carboplatin and nab paclitaxel CI brief — competitive landscape report
- carboplatin and nab paclitaxel updates RSS · CI watch RSS
- Shanghai Henlius Biotech portfolio CI
Frequently asked questions about carboplatin and nab paclitaxel
What is carboplatin and nab paclitaxel?
How does carboplatin and nab paclitaxel work?
What is carboplatin and nab paclitaxel used for?
Who makes carboplatin and nab paclitaxel?
What drug class is carboplatin and nab paclitaxel in?
What development phase is carboplatin and nab paclitaxel in?
What are the side effects of carboplatin and nab paclitaxel?
What does carboplatin and nab paclitaxel target?
Related
- Drug class: All Chemotherapy combination (platinum agent + taxane) drugs
- Target: All drugs targeting DNA (carboplatin); β-tubulin (nab-paclitaxel)
- Manufacturer: Shanghai Henlius Biotech — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer (phase 3 development)
- Indication: Drugs for Ovarian cancer (potential indication)